eligibility_summary
Key eligibility: consent for cell procurement, life expectancy ≥12 weeks, platinum-refractory and currently or previously treated with a PD-1/PD-L1 inhibitor, systemic corticosteroids ≥10 mg prednisone/day permitted (≤10 mg at investigator discretion), women of childbearing potential need negative pregnancy test, adequate organ function. Exclusions: life expectancy <12 weeks, no prior platinum chemo, inadequate organ function.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: iC9.GD2.CAR.IL-15 T cells—an autologous, gene‑modified cellular therapy (biological CAR T). Mechanism: patient T cells are engineered with a 2nd‑generation anti‑GD2 chimeric antigen receptor to recognize and kill GD2‑expressing tumor cells, coexpressed IL‑15 enhances T‑cell survival and expansion, an inducible caspase‑9 (iC9) safety switch allows rapid elimination of the cells to control toxicity. Targets/cells/pathways: GD2 antigen on lung cancer cells (SCLC and NSCLC), T‑cell activation/cytotoxic signaling via CAR (CD3ζ plus co‑stimulatory domain), IL‑15 survival/proliferation pathway, and iCasp9 apoptotic pathway. Design: Early Phase 1, single‑arm, dose‑escalation in platinum‑refractory, PD‑(L)1–treated lung cancer.